TrialBMC cancer2019

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

Houda Bahig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.